Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia by Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Jon E. Arnason, Adam M. Boruchov, Caron A. Jacobson, David C. Fisher, Hari Miskin, Peter Sportelli, Jennifer R. Brown, Matthew S. Davids

Get full text

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

Get full text

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel by Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Zhen-Huan Hu, Michael T. Hemmer, Michael J. Zoratti, Suresh Vunnum, Jonathan Tsang, Clare Spooner, Harry Smith, Christine Fu, Anik Patel, Harry Miao, Shilpa A. Shahani, Debbie L. Mirjah, Hairong Xu, Marcelo C. Pasquini

Get full text

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia by James T. Yoon, Yinglu Zhou, Mariia Mikhaleva, Daniel S. Choi, Stacey M. Fernandes, Philippe Armand, Amy C. Bessnow, Jennifer L. Crombie, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Reid W. Merryman, Oreofe O. Odejide, Erin M. Parry, David A. Qualls, Christine E. Ryan, Aswin Sekar, Jacob D. Soumerai, Jon Arnason, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

Get full text